AllianceBernstein
RPRX icon

AllianceBernstein’s Royalty Pharma RPRX Stock Holding History

AllianceBernstein’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.3M Buy
1,197,718
+176,950
+17% +$7.75M 0.02% 621
2025
Q4 		$39.4M Buy
1,020,768
+83,910
+9% +$3.2M 0.01% 699
2025
Q3 		$33.1M Buy
936,858
+37,016
+4% +$1.34M 0.01% 744
2025
Q2 		$32.4M Sell
899,842
-341,209
-27% -$11.3M 0.01% 737
2025
Q1 		$38.6M Buy
1,241,051
+86,873
+8% +$2.75M 0.01% 653
2024
Q4 		$29.4M Sell
1,154,178
-125,842
-10% -$3.34M 0.01% 785
2024
Q3 		$36.2M Sell
1,280,020
-30,856
-2% -$855K 0.01% 706
2024
Q2 		$34.6M Sell
1,310,876
-133,640
-9% -$3.7M 0.01% 712
2024
Q1 		$43.9M Buy
1,444,516
+75,117
+5% +$2.21M 0.02% 646
2023
Q4 		$38.5M Buy
1,369,399
+1,150,580
+526% +$31.6M 0.01% 665
2023
Q3 		$5.94M Sell
218,819
-3,384
-2% -$101K ﹤0.01% 1345
2023
Q2 		$6.83M Sell
222,203
-69,303
-24% -$2.35M ﹤0.01% 1307
2023
Q1 		$10.5M Buy
291,506
+131,429
+82% +$4.87M ﹤0.01% 1077
2022
Q4 		$6.33M Sell
160,077
-166,182
-51% -$6.94M ﹤0.01% 1315
2022
Q3 		$13.1M Sell
326,259
-60,800
-16% -$2.6M 0.01% 972
2022
Q2 		$16.3M Buy
387,059
+64,360
+20% +$2.64M 0.01% 933
2022
Q1 		$12.6M Buy
322,699
+166,129
+106% +$6.52M ﹤0.01% 1106
2021
Q4 		$6.24M Sell
156,570
-3,309
-2% -$129K ﹤0.01% 1502
2021
Q3 		$5.78M Buy
159,879
+1,070
+0.7% +$41.6K ﹤0.01% 1531
2021
Q2 		$6.51M Buy
158,809
+65,722
+71% +$2.8M ﹤0.01% 1461
2021
Q1 		$4.06M Buy
93,087
+42,915
+86% +$2.03M ﹤0.01% 1690
2020
Q4 		$2.51M Buy
50,172
+9,460
+23% +$401K ﹤0.01% 1851
2020
Q3 		$1.71M Buy
+40,712
New +$1.75M ﹤0.01% 1937

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AllianceBernstein's RPRX Position: Q1 2026 in Review

AllianceBernstein increased its Royalty Pharma (RPRX) stake by 17% in Q1 2026, buying an estimated $7.75M and bringing the position to 1,197,718 shares worth $46.3M. The position accounts for 0.02% of the portfolio, ranked #621.

AllianceBernstein first reported a position in RPRX in Q3 2020 and has held it in 23 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • AllianceBernstein held 1,197,718 shares of Royalty Pharma worth $46.3M as of Q1 2026.
  • AllianceBernstein bought 176,950 Royalty Pharma shares in Q1 2026, an estimated $7.75M.
  • Royalty Pharma made up 0.02% of AllianceBernstein's portfolio in Q1 2026, its #621 holding.
  • AllianceBernstein first reported a position in Royalty Pharma in Q3 2020 and has held it in 23 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.